U.S., Sept. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07192211) titled 'Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo CABG' on Aug. 28.
Brief Summary: ADR-002K is administered to heart failure patients with ischemic heart disease who undergo coronary artery bypass surgery (CABG) to investigate its efficacy and safety.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Ischemic Heart Disease
Intervention:
BIOLOGICAL: Mesenchymal stem cell
ADR-002K administration
BIOLOGICAL: Placebo
Placebo
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Rohto Pharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission f...